BREAKTHROUGH: Acetaminophen Reduces Organ Injury in Sepsis Treatment 

United States: A clinical trial supported by the National Institutes of Health (NIH) has discovered intravenous acetaminophen lowers the risk of sepsis patients. The risks involve organ injury or production of acute respiratory distress syndrome. 

These risks are said to be a serious condition that permits fluid to penetrate into the lungs. Sepsis is the condition when there is uncontrolled as well as extreme response to an infection

More about the trial 

Although the trial did not increase mortality rates in every patient suffering from sepsis, not to mention the severity, according to the scientists, acetaminophen has given a major boost to those who were dealing with organ failure, reported at nih.gov

The findings of the study were published in JAMA. 

Acetaminophen Reduces Organ Injury in Sepsis Treatment. Credit | Shutterstock
Acetaminophen Reduces Organ Injury in Sepsis Treatment. Credit | Shutterstock

With the help of therapy, the patients who required a lesser level of assisted ventilation thus went through a little and insignificant depreciation in death rate. 

In the case of sepsis, RBCs bear the injury and hence die at a very uncommonly high rate, thereby releasing “cell-free hemoglobin” into the blood. 

Previously done work from Lorraine Ware, M.D., professor of medicine, pulmonary and critical care at Vanderbilt University, Nashville, Tennessee, and who is also the first author of the current study, showcased a fact that acetaminophen in plus of relieving pain and lessening fevers, had shown ways to block the harms of cell-free hemoglobin on the lungs. 

According to Michael Matthay, M.D., professor of medicine and anesthesia at the University of California, San Francisco, and the senior study author, “One problem in critical care is the patients get sick so fast, that we do not normally have time to figure out which biomarkers help predict which therapy could give the best outcome,” nih.gov reported. 

He added, “We hope that these findings will underscore the potential therapeutic value of using a biomarker to help successfully find a treatment that will work when patients need it the most.” 

How was the test conducted? 

In order to calculate the therapeutic potential of acetaminophen better during a mid-stage clinical trial. The researchers participated 447 adults with sepsis, as well as respiratory or circulatory organ dysfunction among the 40 US academic hospitals from October 2021 to April 2023. 

James Kiley, Ph.D., director of the Division of Lung Diseases at the National Heart, Lung, and Blood Institute, part of NIH, said, “While the anticipated effects of acetaminophen therapy were not realized for all sepsis patients, this study shows that it still holds promise for the most critically ill,” as nih.gov reported. 

He said, “Though, more research is needed to uncover the mechanisms and validate these results.”